Kajian klinikal Lupus di Arizona
7 kajian untuk Lupus sedang mencari peserta di lokasi di Arizona.
Bandar di Arizona
Teks kajian rasmi (Bahasa Inggeris)
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Sl0044 50058, Avondale
- Sl0044 50550, Chandler
- Sl0044 50713, Gilbert
- dan 3 lagi
Mengambil pesertaFasa 3
Umur 16 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06617325An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Research Site, Phoenix
Mengambil pesertaFasa 3
Umur 5 hingga 17 · Semua jantina · Dikemas kini 30 Sep 2026 · NCT05835310A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Research Site, Phoenix
- Research Site, Tucson
Mengambil pesertaFasa 3
Umur 18 hingga 70 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07430306A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Mayo Clinic, Phoenix
Mengambil pesertaFasa 1
Umur 18 hingga 74 · Semua jantina · Dikemas kini 10 Sep 2026 · NCT07085104A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
- HonorHealth Research and Innovation Institute, Scottsdale
Mengambil pesertaFasa 2
Umur 18 hingga 75 · Semua jantina · Dikemas kini 21 Ogo 2026 · NCT06570798A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
- AARA Clinical Research, Avondale
- AARA Clinical Research, Tucson
Mengambil pesertaFasa 1
Umur 18 hingga 70 · Semua jantina · Dikemas kini 5 Jun 2026 · NCT06613360Lupus Landmark Study: A Prospective Registry and Biorepository
- University of Arizona, Tucson
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 110 · Semua jantina · Dikemas kini 15 Apr 2026 · NCT05934149Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.